Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer’s disease
| dc.contributor.author | Taliyan, Rajeev | |
| dc.date.accessioned | 2023-12-14T10:46:10Z | |
| dc.date.available | 2023-12-14T10:46:10Z | |
| dc.date.issued | 2021-12 | |
| dc.description.abstract | Type-2 Diabetes Mellitus and insulin resistance increases the risk of Alzheimer’s disease (AD). Recent studies highlighted the role of peroxisome proliferator-activated receptor-gamma (PPAR-γ) in modulation of AD. This study was designed to investigate the effect of rosiglitazone alone or in its nanoformulated form for an effective drug delivery in mice model of AD. | en_US |
| dc.identifier.uri | https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.058674 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13431 | |
| dc.language.iso | en | en_US |
| dc.publisher | Alzheimer's Association | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Alzheimer’s disease | en_US |
| dc.subject | Rosiglitazone | en_US |
| dc.title | Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer’s disease | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: